BEVERLY, MA – October 22, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a development update on the Company’s p53 anti-cancer drug candidate Kevetrin. The Company is in the process of selecting a Contract Research Organization to complete the necessary remaining bridging toxicology work toward developing Kevetrin in oral form, which remains the top priority within Innovation Pharmaceutical’s cancer program.
“After completing our Phase 1 Kevetrin study, we were invited by one of the world’s largest pharmaceutical companies to meet at their world headquarters and discuss our results,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “In attendance were the company’s CEO and senior scientists flown in from around the country. The main takeaways from the meeting were twofold. In order to enter into a development deal with them we needed to show p53 modulation in the tumor and develop a Kevetrin formulation as an oral dose. In our Phase 2a trial in ovarian cancer, intra-tumor p53 modulation was observed. Our goal now is to initiate a clinical trial of oral Kevetrin as soon as is feasible. Should clear efficacy be demonstrated, oral Kevetrin—as one of the few p53-modulating drugs in human trials, and in pill or tablet form—could emerge as a frontline treatment for cancer.”
“Independent academic cancer researchers, at Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, with whom we have closely collaborated over the years, are as intrigued as we are by Kevetrin’s considerable promise in treating multiple cancer types,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer of Innovation Pharmaceuticals. “We continue to advance Kevetrin, including efforts to complete the necessary tox studies. An orally-delivered Kevetrin could advantageously position the drug as a future go-to anti-cancer treatment, given that loss of proper p53 functioning is implicated in most cancers, and there is a strong patient preference for oral meds.”
Throughout pre-clinical testing and two successful clinical trials (Phase 1b for advanced solid tumors, Phase 2a for ovarian cancer), Kevetrin demonstrated promising signs of efficacy and a favorable pharmacokinetic profile, including a relatively short biological half-life (less than 2 hours). Preclinical research studies have revealed that Kevetrin exhibits a dose-dependent response in its effect upon cancer cells and clinical results have shown that it clears the body within one day—on average between 8 and 10 hours—though the drug can remain in the body up to roughly 24 hours, depending upon individual patient variations. In addition, oral bioavailability in tested animals is favorable.
The Company believes these characteristics make Kevetrin an ideal candidate for oral delivery—as the clinical dosing form—facilitating convenient and frequent administration, perhaps multiple times daily. Oral delivery would maximize the therapeutic benefit of the compound, whether administered as a monotherapy or in combination with other oncology drugs, including immunotherapies. Currently, pharmaceutical industry, as well as private investment, interest in this area is substantial—an estimated 500 million people alive today will die from p53 mutated cancers. A p53-modulating drug has yet to garner market approval.
The Company plans to provide further program updates once the Kevetrin toxicology studies conclude and oral formulation work commences. In the interim, more information on Kevetrin’s potential as a novel p53-modulating anti-cancer treatment can be found on the Company’s website at the links below: